Clinical trials: Prostatic Neoplasm
Adenocarcinoma, Prostate Neoplasms
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
This study will evaluate the accuracy and effectiveness of an experimental tracking device for locating abnormalities during invasive procedures, such as biopsy or ablation, that cannot easily be visualized by usual imaging…
- Conditions
- Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma
- Trial name
- NCT00102544
- Testing
- EM Tracking
- Where
- United States
- Volunteers
- 3,894 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer Of Prostate, Prostate Cancer
Collection of Blood From Patients With Prostate Cancer
Background: It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
- Conditions
- Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms, Metastatic Prostate Cancer
- Trial name
- NCT00923221
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms, Prostate Cancer
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Background: Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery.
- Trial name
- NCT01834001
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Hormone Sensitive Prostate Cancer, Prostate Cancer
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02319837
- Testing
- Enzalutamide, Leuprolide Open Label
- Where
- 255 sites in United States, Australia and 15 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 582 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Of Prostate, Prostate Neoplasms
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Background: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body.
- Trial name
- NCT04633252
- Testing
- PDS01ADC, Docetaxel, M7824
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per…
- Trial name
- PROSTEP-002 (NCT04655365)
- Testing
- Enzalutamide capsule
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
Precision-Based Genomics in Prostate Cancer
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and…
- Trial name
- NCT04706663
- Where
- 11 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Effectiveness of Cryotherapy Study for Prostate Cancer
This is a single-centre prospective, non-randomized trial to investigate the efficacy of cryotherapy in patients with localized prostate cancer.The aim of study is to investigate the safety profile of cryotherapy in the treatment…
- Trial name
- NCT04978519
- Testing
- Cryotherapy
- Where
- Hong Kong
- Volunteers
- 16 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity.
- Trial name
- PragMet (NCT05515978)
- Testing
- Metformin, Lifestyle Modification
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Colorado, Denver
High-Risk Prostate Cancer
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk…
- Trial name
- SNARE (NCT05593497)
- Testing
- Capivasertib, abiraterone acetate
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer, Prostate Adenocarcinoma
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
- Trial name
- NCT05710380
- Testing
- Risk Map Decision Support System (DSS)., Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging (MRI) Guided Biopsy
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- University of Chicago
Prostatic Neoplasms, Castration-Resistant
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better…
- Trial name
- NCT05743621
- Testing
- TVB-2640, Enzalutamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer, Prostate Adenocarcinoma
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Trial name
- NCT05751434
- Testing
- Exercise Therapy
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- City of Hope Medical Center
Malignant Prostate Neoplasm
Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer
This clinical trial evaluates the feasibility, safety, and tolerability of stereotactic ablative radiotherapy (SABR) using daily adaptive radiation techniques to the prostate fossa and/or pelvic lymph nodes in patients with…
- Trial name
- DAPPER (NCT05830838)
- Testing
- Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Prostate Cancer
Real World Prostate Cancer Registry
Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous…
- Trial name
- RWPCR (NCT06355336)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Cincinnati Cancer Advisors
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA)
This monocentric interventional study investigates whether the Radio-induced Lymphocyte Apoptosis (RILA) assay can predict the occurrence of late radiation-induced toxicities in patients with localized prostate cancer treated…
- Trial name
- PROSTERA (NCT07145437)
- Testing
- Radio-induced Lymphocyte Apoptosis (RILA) Assay, Stereotactic body radiotherapy (SBRT)
- Volunteers
- 220 people
- Sponsor
- Clinique Sainte Clotilde
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.